Clinical Trial News and Research

RSS

Scientists develop new nasal vaccine that proves effective against whooping cough

Scientists involved in the EU-funded project ChildInnovac are about to publish in the online journal Plos One the results of their first clinical trial of a new nasal vaccine.

16 Jan 2014

RTOG phase II clinical trial of Bevacizumab (Avastin) shows positive results for treatment of cervical cancer

An article published in the January issue of the International Journal of Radiation Oncology, Biology and Physics reports results of the Radiation Therapy Oncology Group (RTOG) phase II clinical trial of Bevacizumab (Avastin) in addition to cisplatin and pelvic radiation for locally advanced cervical cancer.

16 Jan 2014

EU-sponsored TumAdoR project targets relationship between immune system and cancer growth

A multinational set of seven teams is banding together to develop a drug that may potentially fight many different cancers through an antibody that would work within the body's metabolic system.

16 Jan 2014

First commercial implant of Elixir's DESolve Novolimus Eluting Coronary Scaffold performed in Germany

Marking a milestone in the evolution of fully-bioresorbable drug-eluting scaffolds for interventional cardiology, the first commercial implant of Elixir Medical's CE Mark-approved DESolve Novolimus Eluting Coronary Scaffold was performed in Germany by Professor Dr. med. Holger Nef, Head of the Cardiac Catheterization Laboratory, University Hospital Giessen, Giessen, Germany.

15 Jan 2014

Virtual reality, dance and fun help in treating urinary incontinence in senior women

Virtual reality, dance and fun are not the first things that come to mind when we think of treating urinary incontinence in senior women. However, these concepts were the foundations of a promising study by Dr. Chantal Dumoulin, PhD, Canada Research Chair in Urogynaecological Health and Aging, a researcher at the Institut universitaire de g-riatrie de Montr-al, and an associate professor in the Physiotherapy Program of the Rehabilitation School at Universit- de Montr-al, and her master's student, Miss Val-rie Elliott.

15 Jan 2014

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

AstraZeneca and Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration approved Farxiga™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

13 Jan 2014

FDA approves Ocular Therapeutix’s ReSure Sealant for ophthalmic use

Ocular Therapeutix announced today it has received approval from the Food and Drug Administration to commercialize the ReSure Sealant in the United States, with an indication for prevention of postoperative fluid egress from incisions with a demonstrated wound leak following cataract surgery.

10 Jan 2014

Altheus Therapeutics completes enrollment for Phase 2 trial of Zoenasa Rectal Gel for distal ulcerative colitis

Altheus Therapeutics, Inc., announced that it has completed enrollment for ZA201, a 6-week, double-blind, active-controlled Phase 2 clinical trial of the efficacy and safety of Zoenasa Rectal Gel in approximately 120 adult patients with left-sided, or distal, ulcerative colitis. Topline results are expected in to be available in March or early April.

9 Jan 2014

Immune tolerance to grafts of muscle, bone and skin could free recipients from lifelong immunosuppression

Massachusetts General Hospital investigators have made an important step towards greater availability of hand transplants, face transplants and other transplants involving multiple types of tissue.

9 Jan 2014

Proteon's PRT-201 gets orphan drug designation for prevention of arteriovenous access dysfunction

Proteon Therapeutics, Inc., a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases, today announced that its lead product, PRT-201, has received orphan drug designation in the European Union for the prevention of arteriovenous access dysfunction in hemodialysis patients.

9 Jan 2014

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors.

9 Jan 2014

Emmaus completes all patient visits for Phase 3 trial of L-glutamine for treatment of sickle cell disease

Emmaus Medical, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of innovative and cost-effective treatments and therapies primarily for rare and orphan diseases, today announced it has completed all patient visits for its Phase 3 clinical trial for the treatment of sickle cell disease. Emmaus expects top-line data from the Phase 3 clinical trial to be available in the first quarter of 2014.

8 Jan 2014

OxThera announces initiation of Oxabact clinical study in Primary Hyperoxaluria

OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in Primary Hyperoxaluria. This announcement bolsters the Company's position as a leader in developing therapies for hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.

8 Jan 2014

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Advanced Inhalation Therapies, an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis.

8 Jan 2014

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

Insight Genetics, Inc. today announced it has received a new $1.5 million Phase II Small Business Innovation Research contract from the National Cancer Institute.

8 Jan 2014

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today the Company has received approval from the United States Food and Drug Administration (FDA) to commence patient screening of a Phase 2b study of PRO 140, a monoclonal CCR5 antibody, for the treatment of patients with Human Immunodeficiency Virus Type 1.

8 Jan 2014

CROS NT acquires MDSL International

As part of the CROS NT Group global growth strategy, CROS NT Ltd today announced the acquisition of MDSL International - a specialist clinical Contract Research Organization (CRO) providing biometrics services such as Clinical Data Management and Statistical services. The financial details of the transaction remain confidential.

8 Jan 2014

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.

8 Jan 2014

Research highlights potential of newly developed radiopharmaceuticals for imaging melanoma metastases

With low survival rates for patients with metastasized melanoma, accurate staging and effective treatments are critical to extending life. New research published in the Journal of Nuclear Medicine highlights the potential of newly developed radiopharmaceuticals with benzamide for the imaging of metastases and as a targeted systemic therapy.

8 Jan 2014

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency.

7 Jan 2014

Clinical Trial News and Research

Scientists develop new nasal vaccine that proves effective against whooping cough

RTOG phase II clinical trial of Bevacizumab (Avastin) shows positive results for treatment of cervical cancer

EU-sponsored TumAdoR project targets relationship between immune system and cancer growth

First commercial implant of Elixir's DESolve Novolimus Eluting Coronary Scaffold performed in Germany

Virtual reality, dance and fun help in treating urinary incontinence in senior women

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

FDA approves Ocular Therapeutix’s ReSure Sealant for ophthalmic use

Altheus Therapeutics completes enrollment for Phase 2 trial of Zoenasa Rectal Gel for distal ulcerative colitis

Immune tolerance to grafts of muscle, bone and skin could free recipients from lifelong immunosuppression

Proteon's PRT-201 gets orphan drug designation for prevention of arteriovenous access dysfunction

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Emmaus completes all patient visits for Phase 3 trial of L-glutamine for treatment of sickle cell disease

OxThera announces initiation of Oxabact clinical study in Primary Hyperoxaluria

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CROS NT acquires MDSL International

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Research highlights potential of newly developed radiopharmaceuticals for imaging melanoma metastases

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery